Our commitment to advancing vision care is about far more than fighting vision loss. It’s about enhancing every aspect of the patient experience, ensuring equitable access to our treatments for all who need them and improving the lives of people with vision-threatening conditions.
True innovation for these patients demands scientific curiosity fueled by passion and rigor. We’re following the science to build an unrivaled ophthalmology pipeline of life-changing treatments that patients need next.
Read personal stories from people living with retinal conditions here:
Learn about Dave’s experience with Diabetic Macular Edema (DME).
Advancing Diversity & Inclusion in Ophthalmology
Serving diverse patient populations starts with inclusive, representative research. We launched the first company-sponsored retinal study of its kind to examine diabetic macular edema (DME) in underrepresented populations – specifically among Black, African American, Hispanic, Latin American, and Indigenous people. We are also conducting additional exploratory ophthalmology research and analyses with a diversity and inclusion focus. Beyond clinical studies, we are advancing diversity and inclusion in ophthalmology by supporting young scientists from underrepresented backgrounds.
Learn more about our long-term efforts to provide equitable care for all people in need.
We invest continually and for the long term – advancing the research, development and expertise needed to improve patients’ lives. Our robust clinical development program is evaluating potential treatments for vision-threatening eye conditions including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), retinal vein occlusion (RVO), geographic atrophy (GA) and more.
Our history of scientific discovery is foundational to our progress in ophthalmology. And since the beginning, our work has been rooted in the needs of patients, who have always driven our unwavering efforts to develop sight-saving therapies. At the same time, we continue to seek new platforms, pathways and technologies in the ongoing fight against vision loss.
Learn more about the field, our research, and the people behind the science.
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials